Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting
April 08, 2022 13:00 ET
|
Werewolf Therapeutics, Inc.
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner WTX-330 surrogate demonstrated significant expansion of the therapeutic...
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
March 24, 2022 07:00 ET
|
Werewolf Therapeutics, Inc.
-Closed upsized IPO in May 2021 raising $120 million in gross proceeds- -Announced clinical trial collaboration with Merck for WTX-124 INDUKINETM program- -Reported positive preclinical data at SITC...
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
March 16, 2022 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
March 15, 2022 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
February 08, 2022 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
January 05, 2022 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Added to the Nasdaq Biotechnology Index
December 14, 2021 16:01 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting
December 01, 2021 08:00 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...
Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
November 10, 2021 07:00 ET
|
Werewolf Therapeutics, Inc.
-Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics,...
Werewolf Therapeutics to Present at Upcoming Conferences in November 2021
November 08, 2021 08:03 ET
|
Werewolf Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated...